BRIEF-Cytokinetics Announces European Commission Approval Of MYQORZO

Reuters
02/17
BRIEF-<a href="https://laohu8.com/S/CYTK">Cytokinetics</a> Announces European Commission Approval Of MYQORZO

Feb 17 (Reuters) - Cytokinetics Inc CYTK.O:

  • CYTOKINETICS ANNOUNCES EUROPEAN COMMISSION APPROVAL OF MYQORZO® (AFICAMTEN) FOR THE TREATMENT OF ADULTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY

  • CYTOKINETICS INC: FIRST EUROPEAN LAUNCH EXPECTED IN GERMANY IN Q2 2026

Source text: ID:nGNXbhJ25h

Further company coverage: CYTK.O

((Reuters.Briefs@thomsonreuters.com;))

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10